Dr. Sax is director of the HIV Program and Division of Infectious Diseases at Brigham and Women's Hospital in Boston.
Well, it will be interesting to see what happens with two-drug maintenance therapy, in general, and in particular with cabotegravir [CAB, GSK1265744] and rilpivirine [Edurant], whether it's as a single, tiny little pill, or it's as an injectable -- if that premise works out. It could really give patients and providers a lot to think about. Whether that's the right approach, we'll see.
[In terms of injectable HIV drugs], as initial treatments, we're not even close. But as a way of maintaining virologic suppression, I do think there will be a subset of patients who will really prefer that it be taken out of their hands, that they're tired of taking pills, that they're not good at taking pills. But if you said to them, "We can give you an injection once a month, or once every two months, and have someone come to your house and do it for you, or have just a community center that you can get it," then they're going to offer that. And that would be very much a change in what we've done.